Clinical trial · no report yet · Phase 2
NCT07085728
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
- NCT07085728 ↗
- Recruiting
- Eastern Cooperative Oncology Group
- 41 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 41 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Myeloma Multiple
- Interventions
- Cyclophosphamide; Bortezomib (VELCADE); Dexamethasone; Daratumumab-hyaluronidase
- Arms
- ARM A (Cy-Bor-Dex) · Active comparator
- ARM B (Dara-Bor-Dex) · Experimental
- Enrollment
- 74 (estimated)
- Primary outcomes
- Renal Response Rate
- Sponsor
- Eastern Cooperative Oncology Group with National Cancer Institute (NCI)
- Start
- Mar 5, 2026
- Primary completion
- Jan 11, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07085728 · updated Sep 14, 2026